Skip to main content
Preclinical brain amyloid elevation could signal future cognitive decline
6/16/2017

Researchers who examined PET, cerebrospinal fluid and cognitive testing data from 445 cognitively healthy adults with an average age of 74 found that 32.2% of those with elevated brain amyloid levels at baseline had symptoms associated with early-stage Alzheimer's disease at four years and 88.2% had developed symptoms at 10 years. Although no effective preclinical interventions are available, the findings in the Journal of the American Medical Association could be applied to educate and help families plan for future illness, researchers said.

Full Story: